Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
---|---|---|---|---|---|---|
Filed 2024-09-13 17:03 Tx date 2024-09-13 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+800,000 vol |
2,576,860 | |
Filed 2024-09-05 13:14 Tx date 2024-09-05 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,000
+50,000 vol $0.10 each |
1,362,313 | |
Filed 2024-07-18 17:34 Tx date 2024-07-18 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
11 - Acquisition or disposition carried out privately
|
+150,000 vol |
626,200 | |
Filed 2024-07-18 17:33 Tx date 2024-07-18 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$30,000
+300,000 vol $0.10 each |
1,312,313 | |
Filed 2024-07-15 17:04 Tx date 2024-07-03 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
36 - Conversion or exchange
|
$5,983
+55,609 vol $0.1076 each |
1,012,313 | |
Filed 2024-06-14 12:40 Tx date 2024-04-12 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
55 - Expiration of warrants
|
-452,429 vol |
476,200 | |
Filed 2024-04-15 12:34 Tx date 2024-04-12 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
55 - Expiration of warrants
|
+452,429 vol |
||
Filed 2024-05-17 13:11 Tx date 2024-05-16 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$3,689
+38,834 vol $0.095 each |
956,704 | |
Filed 2024-05-17 13:10 Tx date 2024-05-16 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Performance Share Units
57 - Exercise of rights
|
-38,834 vol |
189,274 | |
Filed 2024-05-17 13:08 Tx date 2024-05-16 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Performance Share Units
58 - Expiration of rights
|
-38,834 vol |
228,108 | |
Filed 2024-04-15 12:34 Tx date 2024-04-12 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
55 - Expiration of warrants
|
+452,429 vol |
1,381,058 | |
Filed 2024-04-02 16:44 Tx date 2024-04-02 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$3,530
+37,163 vol $0.095 each |
917,870 | |
Filed 2024-04-02 16:42 Tx date 2024-04-02 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
-37,163 vol |
535,343 | |
Filed 2024-01-02 16:53 Tx date 2023-12-29 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
36 - Conversion or exchange
|
$2,695
+24,222 vol $0.1113 each |
880,707 | |
Filed 2023-11-30 17:33 Tx date 2023-11-28 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+1,450,000 vol |
1,776,860 | |
Filed 2023-11-30 17:31 Tx date 2023-11-28 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+550,000 vol |
572,506 | |
Filed 2023-11-30 17:29 Tx date 2023-11-29 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,750
+50,000 vol $0.075 each |
856,485 | |
Filed 2023-10-11 13:54 Tx date 2023-10-10 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
11 - Acquisition or disposition carried out privately
|
+476,200 vol |
928,629 | |
Filed 2023-10-11 13:52 Tx date 2023-10-10 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Debentures 12% Unsecured Convertible Debenture
11 - Acquisition or disposition carried out privately
|
$
+$100 vol $1,000 each |
$100 | |
Filed 2023-10-11 13:50 Tx date 2020-04-07 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Debentures 12% Unsecured Convertible Debenture
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2023-05-01 13:37 Tx date 2023-04-28 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$3,368
+25,910 vol $0.13 each |
806,485 | |
Filed 2023-05-01 13:36 Tx date 2023-04-28 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
-25,910 vol |
22,506 | |
Filed 2023-04-05 14:47 Tx date 2023-04-05 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$9,900
+100,000 vol $0.099 each |
780,575 | |
Filed 2023-03-31 13:46 Tx date 2023-03-30 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Options
38 - Redemption, retraction, cancellation, repurchase
|
-412,400 vol |
326,860 | |
Filed 2023-03-31 13:42 Tx date 2023-03-30 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,067.13
-11,857 vol $0.09 each |
680,575 | |
Filed 2023-03-31 13:41 Tx date 2023-03-30 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$3,158
+37,162 vol $0.085 each |
692,432 | |
Filed 2023-03-31 13:39 Tx date 2023-03-30 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
-37,162 vol |
48,416 | |
Filed 2022-11-10 15:38 Tx date 2022-11-10 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$6,750
+50,000 vol $0.135 each |
655,270 | |
Filed 2022-09-20 15:44 Tx date 2022-09-20 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,900
+40,000 vol $0.1225 each |
605,270 | |
Filed 2022-09-15 16:26 Tx date 2022-09-15 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$12,150
+90,000 vol $0.135 each |
565,270 | |
Filed 2022-09-13 16:47 Tx date 2022-09-09 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,650
+30,000 vol $0.155 each |
475,270 | |
Filed 2022-05-05 12:17 Tx date 2022-05-02 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,936.32
-8,068 vol $0.24 each |
445,270 | |
Filed 2022-05-05 12:16 Tx date 2022-05-02 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$6,736
+25,909 vol $0.26 each |
453,338 | |
Filed 2022-05-05 12:15 Tx date 2022-05-02 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
-25,909 vol |
85,578 | |
Filed 2022-04-25 14:01 Tx date 2022-04-22 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Options
97 - Other
|
-100,000 vol |
739,260 | |
Filed 2022-04-25 13:59 Tx date 2022-04-20 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Performance Share Units
56 - Grant of rights
|
+111,486 vol |
266,942 | |
Filed 2022-04-25 13:58 Tx date 2022-04-20 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+111,487 vol |
111,487 | |
Filed 2022-04-25 13:57 Tx date 2020-04-07 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2022-04-25 13:56 Tx date 2022-04-20 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
839,260 | |
Filed 2021-05-03 18:55 Tx date 2021-04-28 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Performance Share Units
30 - Acquisition or disposition under a purchase/ownership plan
|
+155,456 vol |
155,456 | |
Filed 2021-05-03 18:54 Tx date 2020-04-07 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Performance Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2021-05-03 18:54 Tx date 2021-04-28 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$321,620
+200,000 vol $1.61 each |
789,260 | |
Filed 2021-04-08 18:08 Tx date 2021-03-01 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
+40,000 vol |
427,429 | |
Filed 2021-04-08 18:07 Tx date 2021-03-01 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
-40,000 vol |
452,429 | |
Filed 2020-10-30 17:42 Tx date 2020-10-29 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
15 - Acquisition or disposition under a prospectus
|
+40,000 vol |
492,429 | |
Filed 2020-10-30 17:41 Tx date 2020-10-29 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
15 - Acquisition or disposition under a prospectus
|
$52,000
+80,000 vol $0.65 each |
387,429 | |
Filed 2020-06-29 17:23 Tx date 2020-04-07 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
452,429 | ||
Filed 2020-06-29 17:22 Tx date 2020-04-07 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
589,260 | ||
Filed 2020-06-29 17:21 Tx date 2020-04-07 |
$WLLW
Willow Biosciences Inc. |
Savile, Christopher Kenneth
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
307,429 |